Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Five Below Inc (FIVE) vs Novo Nordisk A/S (NVO) Price & Performance

Five Below IncTrade
Novo Nordisk A/STrade

Price performance (Past 24H)

Key statistics

Five Below Inc vs Novo Nordisk A/S — how do they compare? Five Below Inc trades at $234.71 (market cap $13.01B), while Novo Nordisk A/S trades at $47.23 (market cap $207.31B). The key difference: Novo Nordisk A/S is far larger — about 15.9× Five Below Inc's market cap, and Novo Nordisk A/S pays a 3.76% dividend while Five Below Inc pays none. Which is the better fit depends on your goals.

FIVENVO
Market Cap
$13.01B$207.31B
Sector
Consumer StaplesHealth
52-Week High
$247.71$63.98
52-Week Low
$131.94$35.29
Enterprise Value
$13.90B$222.02B
Dividend Yield
3.76%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Five Below Inc

Five Below (FIVE) is trading at $244.37, up 5.73% with strong bullish momentum. The stock shows consistent earnings beats, with Q1 2026 EPS of $2.22 exceeding expectations of $1.77. Technical indicators signal bullish sentiment, supported by positive moving averages. Revenue growth remains solid, projected to reach $5.1B in 2026, though net margins have compressed from 9.78% in 2022 to 6.54% in 2025. Analyst consensus is strongly bullish with 62% buy ratings and a $252.36 price target.

FIVE presents a compelling growth story with expanding revenue and strong institutional support. However, elevated valuation multiples (P/E 30.79) and compressed profit margins pose risks. The stock's proximity to 52-week highs suggests limited near-term upside without significant catalysts. Execution on store expansion and margin improvement will be critical for sustained outperformance.

Novo Nordisk A/S

Novo Nordisk (NVO) trades at $47.26, up 2.79% today, with a neutral technical signal and strong fundamentals including a P/E of 11.67 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but shares faced pressure from competitive concerns and pipeline setbacks. Cash flow remains robust with $10.81B net cash flow in 2025, while debt-to-asset ratio rose to 20.61% in 2024.

Outlook is mixed: solid profitability and analyst buy consensus (57.9%) support upside, but competition from Eli Lilly and pricing headwinds pose risks. Revenue growth is steady, with 2026 guidance lifted, yet investor sentiment is cautious amid operational challenges and high expectations for Wegovy pill performance.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Five Below Inc

Five Below is a value-oriented retailer that operated 1,190 stores in the United States as of the end of fiscal 2021. Catering to teen and preteen consumers, stores feature a wide variety of merchandise, the vast majority of which is priced below $6. The assortment focuses on discretionary items in several categories, particularly leisure (such as sporting goods, toys, and electronics

Read more on FIVE

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Read more on NVO